Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 150Colorectal Neoplasms 82Stomach Neoplasms 77Neoplasms 35Neoplasm Metastasis 35Pancreatic Neoplasms 25Triple Negative Breast Neoplasms 22Parkinson Disease 4, Autosomal Dominant Lewy Body 16Adenocarcinoma 13Esophageal Neoplasms 12Carcinoma, Non-Small-Cell Lung 11Colonic Neoplasms 10Biliary Tract Neoplasms 10Rectal Neoplasms 9Carcinoma, Hepatocellular 9Brain Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Adenocarcinoma Of Esophagus 7Solid Tumor 6Ovarian Neoplasms 6Cholangiocarcinoma 6Nasopharyngeal Carcinoma 5Gastrointestinal Neoplasms 5Esophageal Squamous Cell Carcinoma 5Recurrence 4Nasopharyngeal Neoplasms 4Advanced Solid Tumors 4Sarcoma 3Melanoma 3Head and Neck Neoplasms 3

Interventions

Gemcitabine 3130-nm albumin-bound paclitaxel 2Taxes 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Pancreatic Ductal Adenocarcinoma × Capecitabine × Clear all
NCT07024615 2026-05-28

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

Astellas Pharma Inc

Phase 1 Recruiting
25 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡